Axsome Therapeutics
AXSM
292 hedge funds and large institutions have $3.15B invested in Axsome Therapeutics in 2024 Q4 according to their latest regulatory filings, with 62 funds opening new positions, 91 increasing their positions, 89 reducing their positions, and 40 closing their positions.
55% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 40
49% more call options, than puts
Call options by funds: $181M | Put options by funds: $121M
38% more funds holding in top 10
Funds holding in top 10: 8 → 11 (+3)
5% more funds holding
Funds holding: 278 → 292 (+14)
2% more repeat investments, than reductions
Existing positions increased: 91 | Existing positions reduced: 89
3.81% less ownership
Funds ownership: 80.54% → 76.73% (-3.8%)
9% less capital invested
Capital invested by funds: $3.47B → $3.15B (-$328M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lazard Asset Management
New York
|
+$41.5M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$31.5M |
| 3 |
Principal Financial Group
Des Moines,
Iowa
|
+$18.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$17.5M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
+$15.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$81.9M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$77M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$48.1M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$42.8M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$32.9M |
AXSM Hedge Fund Activity: Q4 2024 in Review
292 of the 7,606 institutional investors tracked by Wall St. Rank reported a position in Axsome Therapeutics (AXSM) for Q4 2024, worth a combined $3.15B — down 9.4% from $3.47B a quarter earlier.
Buyers outnumbered sellers: 62 funds opened new AXSM positions and 40 closed out — a net gain of 22 holders — while 91 added to existing stakes and 89 trimmed.
The largest buyer was Lazard Asset Management, adding an estimated $41.5M. The largest seller was Fairmount Funds Management, cutting an estimated $81.9M.
- 292 institutional investors held Axsome Therapeutics (AXSM) as of Q4 2024, up from 278 in Q3 2024.
- Funds reported $3.15B of Axsome Therapeutics stock for Q4 2024, down 9.4% quarter-over-quarter.
- 62 funds opened new Axsome Therapeutics positions in Q4 2024 and 40 closed out, a net change of +22 holders.
- The largest Axsome Therapeutics buyer in Q4 2024 was Lazard Asset Management, an estimated $41.5M added.
- The largest Axsome Therapeutics seller in Q4 2024 was Fairmount Funds Management, an estimated $81.9M sold.
Based on aggregated 13F filings for Q4 2024.